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David J. VanderWeele1*, Gladell P. Paner 2, Gini F. Fleming1 and Russell Z. Szmulewitz1
1 Department of Medicine, University of Chicago, Chicago, IL, USA, 2 Department of Pathology, University of Chicago,
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Solid tumors harboring BRCA1 or BRCA2 mutations have been shown to respond
to PARP inhibitors. These responses are partial and transient. In this case report, we
describe an 82-year-old male with poorly differentiated prostate cancer with metastases
to the lung, liver, abdomen, and bowel. Molecular testing demonstrated alterations in
BRCA2, ERG, and TP53. Based on this result, he was enrolled in a therapeutic trial and
received carboplatin, gemcitabine, and veliparib, to which he had a partial response. He
continued to respond while on veliparib maintenance alone, and after 38 cycles he had a
sustained complete response. A sustained complete response to PARP inhibitor-based
therapy has not previously been described for prostate cancer. This case suggests that
cytotoxic therapy in combination with PARP inhibitors may yield exceptional responses,
and molecular studies may help guide patient selection for these therapies.
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Introduction
Though genetic alterations serve as a biomarker to guide the use of targeted therapy for many
solid tumors, this is rarely employed for prostate cancer. Given the important role of the androgen
receptor (AR) in prostate cancer (1), AR-targeted therapies are the backbone of therapy for almost
all patients and no specific genetic test is warranted. Emerging data suggest, however, that for some
patients specific genetic derangements may predict response to additional therapies. Preclinical
data indicate that tumors that harbor an ETS family rearrangement, such as TMPRSS2-ERG, the
most frequent cancer rearrangement, may be responsive to PARP inhibitors (2). Those with a
neuroendocrine phenotype typically harbor amplification or overexpression of AURKA or MYCN
and are hypothesized to respond to an AURKA inhibitor (3). Clinical trials are underway to evaluate
the use of PARP inhibitors (NCT01576172) and AURKA inhibitors (NCT01799278) based on
genetic features.
Men who are carriers of BRCA2 mutations are at higher risk of developing prostate cancer
than non-carriers, and when they are diagnosed with prostate cancer, it tends to be with higher
grade, more aggressive disease (4–6). Evidence from prostate cancer and other tumor types has
shown efficacy of PARP inhibitors for tumors with BRCA1 or BRCA2 alterations (7–9), but
without complete responses. Preclinical data from the TP53-altered prostate cancer line PC3 have
demonstrated synergy between veliparib and cytotoxic therapies (10), and those with alterations
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in ATM, another DNA-damage response gene, have also been
reported to respond to PARP inhibitors (11).
We present here a patient with an aggressive prostate can-
cer with visceral metastases harboring a BRCA2 deletion and
TMPRSS2-ERG rearrangement, alongwithTP53 alteration. Based
on his BRCA2 deletion, he was enrolled in a clinical trial and
treated with carboplatin, gemcitabine, and the PARP inhibitor
veliparib. He had a complete response to therapy, and continues
on veliparib maintenance therapy 30months after enrolling in the
trial, with no evidence of disease. To our knowledge, this is the
first report of complete response to PARP inhibitor-based therapy
for a patient with prostate cancer.
Case Report
The patient, an 82-year-old man, underwent a surgical procedure
at age 61 for treatment of urinary retention due to benign prostatic
hypertrophy. Twelve years later, he developed similar symptoms,
and a prostate biopsy was performed, showing conventional ade-
nocarcinoma of the prostate, Gleason score 4+ 3= 7. He under-
went external beam radiation therapy, and his PSA nadired at
0.5 ng/ml but rose to 13.5 ng/ml 3 years after radiation therapy.
He began androgen deprivation therapy (ADT) with a luteiniz-
ing hormone-releasing hormone analog. Despite this, over the
next few years he had multiple surgical procedures for continued
urinary retention.
A transurethral resection of the prostate performed 6 years
after radiation therapy showed sarcomatoid prostatic adenocar-
cinoma involving the prostatic urethra and bladder neck. Due
to persistent hematuria and lower urinary tract symptoms, the
patient underwent a salvage cystoprostatectomywith ileal conduit
and descending loop colostomy. Pathology revealed high-grade
prostatic adenocarcinoma with extensive sarcomatoid and focal
neuroendocrine differentiation diffusely involving the prostate
and extending into the seminal vesicles, urinary bladder wall
including mucosa and large bowel wall, pT4N0 with 20 regional
lymph nodes negative for malignancy (Figure 1). His PSA at the
time of cystoprostatectomy was<0.05 ng/ml.
The patient continued on ADT following cystoprostatectomy
but developed recurrence of his disease, with radiographically
detected masses within the pelvis and lungs 10months after his
surgery. His PSA remained undetectable. An endoscopic biopsy
of a colonic mass showed poorly differentiated carcinoma invad-
ing colonic mucosa. The tumor cells exhibited similar morpho-
logic features to those in the cystoprostatectomy specimen. He
remained minimally symptomatic and was managed conserva-
tively. Six months after his recurrence, he developed worsen-
ing rectal bleeding. Sigmoidoscopy showed progression of his
metastatic disease in his rectum. Imaging confirmed bowel wall
thickening and showed other pelvic disease; progression of his
lung metastases, largest measuring 3.5 cm; and new liver metas-
tases, the largest 3.1 3.0 cm (Figure 2A).
Tumor tissue from the patient’s cystoprostatectomy was sent
to Foundation One for genetic testing. Three genomic alter-
ations were identified: BRCA2 loss, TMPRSS2-ERG fusion, and
TP53 F270V. The BRCA2 loss and TMPRSS2-ERG translocation
both suggested that he may have increased sensitivity to a PARP
FIGURE 1 | H & E stain of poorly differentiated prostate cancer.
Representative image of high-grade prostate carcinoma from the
cystoprostatectomy specimen exhibiting cribriform pattern and cell necrosis.
FIGURE 2 | Complete resolution of metastatic disease in response to
cytotoxic therapy and veliparib. Computed tomography images showing
pulmonary (top panel, arrow) and liver (bottom panel, arrow) metastases at
baseline (A), after completion of cytotoxic therapy and veliparib (B), and after
38 cycles of veliparib maintenance therapy (C).
inhibitor, and he provided consent for and was enrolled in an
Internal Review Board-approved phase I clinical trial for patients
with documented BRCA1/BRCA2 mutations (NCT01063816,
IRB 09267) consisting of six 21-day cycles of carboplatin AUC= 4
day 1, gemcitabine 800mg/m2 days 1 and 8, and veliparib 250mg
PO BID daily, to be followed by veliparib 250mg PO BIDmainte-
nance therapy. The patient’s course was complicated by diarrhea,
thrombocytopenia, anemia requiring transfusion, and fatigue.
Veliparib was held in cycle 2 for thrombocytopenia, and restarted
with cycle 3 at 210mg PO BID. Gemcitabine was reduced to
400mg/m2 on cycle 3 day 8.
Restaging radiographic imaging was performed after three
cycles of therapy, which showed a partial response within the
liver and lungs. The rectal bleeding had resolved at this time.
The patient completed three additional cycles of therapy, dose
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reduced due to thrombocytopenia and consisting of carboplatin
AUC= 4 day 1, gemcitabine 400mg/m2 day 1, and veliparib
210mg PO BID. Thrombocytopenia and diarrhea resolved, and
anemia and fatigue improved. Repeat staging at the completion of
six cycles showed continued decrease in size of lung metastases,
stable liver metastases, and resolution of bowel wall thicken-
ing (Figure 2B). He started maintenance therapy with veliparib
210mg POBID and continued to have improvement in his metas-
tases. Ten months after completion of therapy, he had complete
resolution of all sites of metastatic disease, and after 38 cycles of
therapy continues to have no evidence of disease (Figure 2C).
Currently he continues on veliparib therapywithminimal toxicity.
Discussion
One could consider castration the first molecularly targeted ther-
apy in oncology, reducing activity of AR, which drives prostate
cancer growth and proliferation. Since castration was described
as effective therapy for prostate cancer seven decades ago, few
therapies for prostate cancer have found targets beyond AR. That
is beginning to change, however, with therapies targeting PARP
and AURKA now in clinical trials for the disease. As the develop-
ment of these therapies progresses, we needways to identify which
patients will most benefit from these therapies.
We describe here a complete response to veliparib-containing
therapy in a patient with BRCA2 deletion, TMPRSS2-ERG
translocation, and TP53 mutation. Preclinical and clinical evi-
dence suggest that all three alterations may contribute to the
patient’s dramatic response to therapy.
Sensitivity of tumors harboring ERG translocations to PARP
inhibitors appears to be dependent on expression of ERG and
interaction between ERG and DNAPK. Hormone naïve cancers
harboring ERG rearrangements typically express ERG protein,
whereas those lacking ERG rearrangements do not. For those
with lethal, castrate-resistant disease, however, ERG expression
is variable despite the presence of ERG translocation (12). Since
expression of the PSA gene KLK3 is regulated by AR, as is
TMPRSS2, the patient’s low PSA value suggested that ERGmight
not be expressed. ERG expression was confirmed, however, with
immunohistochemical analysis (Figure 3).
TMPRSS2-ERG is the most frequent genomic alteration
described in localized prostate cancer, with 40–50% of patients
harboring this translocation, and others harboring rearrange-
ments involving other ETS family members (13, 14). BRCA2
alterations are less common, but those with germline BRCA2
alterations are known to be at high risk of prostate cancer diag-
nosis and high risk of having aggressive disease. It is likely that
those with aggressive disease are more likely to harbor these
particular alterations. Indeed, in cases of localized prostate cancer
sequenced by The Cancer Genome Atlas project, the percent of
patients with ERG fusions, BRCA2 deletion or mutation, or both
is 35, 4, and 2%, respectively. A recent report on castrate-resistant
prostate cancer found that 7% of cases havemissense or truncating
mutations in BRCA2, and an additional 12% have alterations in
other DNA repair/recombination genes associated with response
to PARP inhibitors (15). In cases of end-stage prostate cancer
sequenced by the University of Michigan (16), the percent of
FIGURE 3 | ERG expression in prostate tumor. Immunohistochemical
analysis of the primary tumor. ERG expression is indicated by brown
chromogen in the nucleus. Blue represents hematoxylin counterstain.
patients with ERG fusions, BRCA2 deletion or mutation, or both
is 48, 13, and 8%, respectively. Of those harboring both BRCA2
and ERG alterations, 40% also harbor a deletion in TP53. Though
the percentages are small, given the large number of patients with
metastatic prostate cancer, this may represent a large cohort of
patients who could be considered for therapy similar to what
our patient received. It is possible that alterations in other DNA-
damage pathway genes in addition to TP53 would sensitize to
PARP inhibitors. The hypothesis that patients with similar known
genetic alterations will benefit from a similar treatment regi-
men needs to be tested in the setting of a prospective clinical
trial.
It is unknown if all the components of this therapeutic regimen
were necessary in order for this patient to achieve his therapeutic
success, as he received carboplatin and gemcitabine in addition to
veliparib. However, his disease continued to respond to veliparib
alonewithout achieving a complete response until 10months after
completion of cytotoxic chemotherapy, supporting the notion
that there was additional benefit to the veliparib. Although it is
conceivable that the patient could have responded to the PARP
inhibitor alone (8), other data suggest synergy with cytotoxic ther-
apy (17–21). The optimal duration of treatment is also unknown
in this case. The patient has had a sustained complete response
32 cycles after completion of chemotherapy, on veliparib alone.
It is unknown if discontinuing veliparib would result in disease
recurrence or continued durable response.
Intentionally designed, targeted therapies offer much hope for
the treatment of advanced malignancy but often fail to meet
expectations. Better combinations of therapy, better biomarkers,
or both are needed to help guide therapy decisions. Exploration of
the molecular characteristics of those with exceptional responses
to therapy is an important tool in improving the use of the
therapies we have at hand.
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